Mayank Bhandari

Novel modalities carry huge potential. 1 Within oncology, for example, cell therapy is expected to become the third-largest segment across all modalities (behind antibodies and small molecules) by 2030, with 35 percent CAGR in sales over 2021–30 (Exhibit 1). Gene- and RNA-based therapies, on the other hand, are unlikely to play a major role in the short to medium term, although there are currently more than one hundred such assets in Phase I–III studies.